Pediatrix Medical Group Provides Second Quarter Update
Pediatrix confirmed its second quarter payor mix remained stable, countering recent reports of unfavorable shifts in utilization and reimbursement trends across the healthcare sector. The company reaffirmed its previously issued full year 2026 outlook for Adjusted EBITDA, maintaining the range of $280 million to $300 million. Full results for the quarter ended June 30, 2026 will be released before market open on August 4, followed by a conference call at 9:00 a.m.
Key figures
- Adjusted ebitda
- $280 million to $300 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.